Dialysis and kidney transplantation
The decision to initiate kidney replacement therapy integrates symptoms, refractory biochemical disturbances, volume status, trajectory and patient goals. A filtration estimate alone is not a universal trigger. Hemodialysis, peritoneal dialysis, transplantation and conservative kidney management involve different burdens and benefits. Vascular access planning should fit an individualized kidney-failure life plan rather than treating one access type as best for every patient regardless of anticipated course.
Distinguish diffusion from convection. Hemodialysis removes solutes mainly along concentration gradients; hemofiltration couples solute removal to ultrafiltration with replacement fluid. Combined modalities use both mechanisms. Treatment dose, treatment duration, residual function and interruptions all influence delivered clearance. A urea reduction ratio can be calculated from paired measurements but does not independently describe all aspects of an adequate or tolerable treatment.
Assess instability during treatment systematically. Excessively rapid fluid removal may contribute to cramps or hypotension, but infection, arrhythmia and other emergencies must also be considered. Abrupt neurological symptoms during an initial high-clearance treatment suggest disequilibrium among other diagnoses. Access pain, a cold hand, absent distal pulses or a change in the access examination calls for appropriate evaluation. Cloudy peritoneal effluent with abdominal pain requires timely sampling and an applicable treatment protocol, not waiting for final culture results before any response.
Transplantation introduces immunologic, infectious and pharmacologic risks. Sensitization and donor-specific antibodies affect compatibility, but the type of crossmatch and the complete transplant strategy matter. Rising creatinine after transplantation is not synonymous with rejection: volume changes, obstruction, drug toxicity, infection and recurrent disease can produce similar laboratory changes. Histology, antibody findings and viral testing help distinguish mechanisms. An isolated marker or an imprecise label such as chronic allograft nephropathy cannot establish one cause.
Calcineurin inhibitors have a narrow therapeutic window and important interactions. A high concentration with compatible biopsy findings supports toxicity, while reducing immunosuppression to address infection may increase rejection risk. BK-associated disease often requires coordinated adjustment of immunosuppression. CMV disease depends partly on donor-recipient serostatus, prophylaxis and the net state of immune suppression. Drug doses and prophylaxis durations must account for kidney function and the current transplant protocol. Written foundation questions do not assess procedural skill, replace a transplant team or establish Egyptian program-specific requirements.